Literature DB >> 26369536

Drug interaction databases in medical literature: transparency of ownership, funding, classification algorithms, level of documentation, and staff qualifications. A systematic review.

Gertrud Gansmo Kongsholm1, Anna Katrine Toft Nielsen1, Per Damkier2,3.   

Abstract

PURPOSE: It is well documented that drug-drug interaction databases (DIDs) differ substantially with respect to classification of drug-drug interactions (DDIs). The aim of this study was to study online available transparency of ownership, funding, information, classifications, staff training, and underlying documentation of the five most commonly used open access English language-based online DIDs and the three most commonly used subscription English language-based online DIDs in the literature.
METHODS: We conducted a systematic literature search to identify the five most commonly used open access and the three most commonly used subscription DIDs in the medical literature. The following parameters were assessed for each of the databases: Ownership, classification of interactions, primary information sources, and staff qualification. We compared the overall proportion of yes/no answers from open access databases and subscription databases by Fisher's exact test-both prior to and after requesting missing information.
RESULTS: Among open access DIDs, 20/60 items could be verified from the webpage directly compared to 24/36 for the subscription DIDs (p = 0.0028). Following personal request, these numbers rose to 22/60 and 30/36, respectively (p < 0.0001). For items within the "classification of interaction" domain, proportions were 3/25 versus 11/15 available from the webpage (P = 0.0001) and 3/25 versus 15/15 (p < 0.0001) available upon personal request.
CONCLUSION: Available information on online available transparency of ownership, funding, information, classifications, staff training, and underlying documentation varies substantially among various DIDs. Open access DIDs had a statistically lower score on parameters assessed.

Entities:  

Keywords:  Algorithms; Classification; Documentation; Drug-drug interaction databases; Transparency

Mesh:

Year:  2015        PMID: 26369536     DOI: 10.1007/s00228-015-1943-7

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  30 in total

1.  Concordance of severity ratings provided in four drug interaction compendia.

Authors:  Jacob Abarca; Daniel C Malone; Edward P Armstrong; Amy J Grizzle; Philip D Hansten; Robin C Van Bergen; Richard B Lipton
Journal:  J Am Pharm Assoc (2003)       Date:  2004 Mar-Apr

2.  Evaluation of three brands of drug interaction software for use in intensive care units.

Authors:  Adriano Max Moreira Reis; Silvia Helena De Bortoli Cassiani
Journal:  Pharm World Sci       Date:  2010-10-21

3.  Lack of drug interaction conformity in commonly used drug compendia for selected at-risk dermatologic drugs.

Authors:  Stephanie D Chao; Howard I Maibach
Journal:  Am J Clin Dermatol       Date:  2005       Impact factor: 7.403

4.  Evaluation of the performance of drug-drug interaction screening software in community and hospital pharmacies.

Authors:  Jacob Abarca; Lisa R Colon; Victoria S Wang; Daniel C Malone; John E Murphy; Edward P Armstrong
Journal:  J Manag Care Pharm       Date:  2006-06

Review 5.  Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia.

Authors:  Chen-May Wong; Yu Ko; Alexandre Chan
Journal:  Ann Pharmacother       Date:  2008-11-25       Impact factor: 3.154

6.  Black box warning contraindicated comedications: concordance among three major drug interaction screening programs.

Authors:  Lorraine M Wang; Maple Wong; James M Lightwood; Christine M Cheng
Journal:  Ann Pharmacother       Date:  2009-12-29       Impact factor: 3.154

7.  Clinical decision support and malpractice risk.

Authors:  Michael Greenberg; M Susan Ridgely
Journal:  JAMA       Date:  2011-07-06       Impact factor: 56.272

8.  Improving clinical decision support tools - challenges and a way forward.

Authors:  Michelle Sweidan; James Reeve; Jonathan Dartnell; Stephen Phillips
Journal:  Aust Fam Physician       Date:  2011-08

9.  Customizing clinical decision support to prevent excessive drug-drug interaction alerts.

Authors:  John R Horn; Philip D Hansten; Jacqueline D Osborn; Pamela Wareham; Shabir Somani
Journal:  Am J Health Syst Pharm       Date:  2011-04-15       Impact factor: 2.637

Review 10.  Drug-drug interaction software in clinical practice: a systematic review.

Authors:  Tina Roblek; Tomaz Vaupotic; Ales Mrhar; Mitja Lainscak
Journal:  Eur J Clin Pharmacol       Date:  2014-12-23       Impact factor: 2.953

View more
  5 in total

1.  Drug Interactions in Space: a Cause for Concern?

Authors:  Erez Berman; Sara Eyal
Journal:  Pharm Res       Date:  2019-05-31       Impact factor: 4.200

2.  A retrospective comparison of inappropriate prescribing of psychotropics in three Norwegian nursing homes in 2000 and 2016 with prescribing quality indicators.

Authors:  Jan Schjøtt; Jörg Aßmus
Journal:  BMC Med Inform Decis Mak       Date:  2019-05-29       Impact factor: 2.796

3.  The Possibility of Therapeutic Drug Monitoring of the Most Important Interactions in Nursing Homes.

Authors:  Pernille Schjøtt; Martina Šutovská; Jan Schjøtt
Journal:  Curr Clin Pharmacol       Date:  2019

4.  Potential drug-drug interactions of antiretrovirals and antimicrobials detected by three databases.

Authors:  Pornpun Vivithanaporn; Teetat Kongratanapasert; Bovornpat Suriyapakorn; Pichayut Songkunlertchai; Patpicha Mongkonariyawong; Patanachai K Limpikirati; Phisit Khemawoot
Journal:  Sci Rep       Date:  2021-03-17       Impact factor: 4.379

5.  Use of References in Responses from Scandinavian Drug Information Centres.

Authors:  Jan Schjøtt; Ylva Böttiger; Per Damkier; Linda Amundstuen Reppe; Jens Peter Kampmann; Hanne Rolighed Christensen; Olav Spigset
Journal:  Medicines (Basel)       Date:  2018-07-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.